Daylight therapy as a novel treatment for myopia (short-sightedness)

Phase 2

Completed

• Conditions: Myopia; Eye Diseases

• Registration Number: ISRCTN25433872
• Lead Sponsor: Glasgow Caledonian University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-13
• Study Completion: 2024-09-08
• Last Update Posted: 9 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Healthy children aged over 7 years and younger than 13 years
2. Minimum amount of -0.50 D spherical equivalent refraction (SER) of myopia
3. Best corrected distance visual acuity of at least 0.3 logMAR in each eye (healthy level of vision)

Exclusion Criteria

1. Myopia level of -10D or greater in either eye
2. Astigmatism of 4D or greater in either eye
3. Presence of significant ocular comorbidities
4. Amblyopia in either eye
5. Allergy to cyclopentolate eye drops
6. Use of atropine eye drops in the previous year
7. Taking melatonin supplements
8. Travelled across more than one time zone in the past month

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Axial length measured using biometry at baseline and 6 months

Secondary Outcome Measures

Name	Time	Method
1. Refractive error measured using cycloplegic autorefraction at baseline and 6 months<br>2. Salivary melatonin measured using a commercial ELISA kit at baseline and 6 months<br>3. Tolerability measured using participant questionnaire at baseline, 3 months and 6 months